SF3B1 and B-cell chronic lymphocytic leukemia: Clinically, SF3B1 mutations are associated with an aggressive CLL phenotype, characterized by shorter treatment-free survival, poor response to fludarabine-based chemoimmunotherapy, and increased risk of disease progression [194].